Lumiflavin

Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer^[1][2][3]. In Vitro:Lumiflavin (10-40 μM, 48 h) has synergistic effects with Diamminedichloroplatinum (DDP) (20 μM, 48 h) on CSCs in increasing mitochondrial function damage and apoptosis rates and decreasing clonic function^[2].
Lumiflavin (0-80 μM, 72 h) reduces the formation of drug resistance and proportion of CSCs, increases CSCs/DDP apoptosis rate and reduces cell clone formation ability in ovarian cancer cell line OVCAR-3^[3].
Lumiflavin (80 μM, 72 h) downregulates the protein expression of Notch signaling pathway in CSCs/DDP^[3].
In Vivo:Lumiflavin (8 mg/kg, i.p., once a day for 25 days) has a synergistic cytotoxic effect on an ovarian cancer nude mice model by enhancing the DNA‐damage response and increasing the apoptotic protein expression^[2].
Lumiflavin (4-16 mg/kg, s.c., once a day for 25 days) combined with DDP reduces tumor weight and inhibits tumor growth^[3].